Data availability
Not applicable.
Code availability
Not applicable.
References
Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, Fleming N, Domingues V, Sciascia S, Lyra JO, Petri M, Khamashta M, Levy RA (2015) The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on antiphospholipid syndrome clinical features. Autoimmun Rev 14:401–414. https://doi.org/10.1016/j.autrev.2015.01.002
Zhu DS, Fu J, Zhang Y, Li SX, Zhang GX, Guan YT, Dong Q (2014) Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics. J Neurol Sci 346:138–144. https://doi.org/10.1016/j.jns.2014.08.010
Cecchi I, Radin M, Rubini E, Foddai SG, Barinotti A, Roccatello D, Sciascia S (2021) Clinical manifestations in patients with antiphospholipid antibodies: beyond thrombosis and pregnancy loss. Lupus 0961203321:884–892. https://doi.org/10.1177/0961203321995248
Sciascia S, Radin M, Cecchi I, Bertolaccini ML, Bertero MT, Rubini E, Vaccarino A, Bazzan M, Giachino O, Baldovino S, Rossi D, Mengozzi G, Roccatello D (2021) Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. Rheumatology 60:1106–1113. https://doi.org/10.1093/rheumatology/kez596
Ogino S, Iwamoto K, Yamamoto H, Yamaguchi K, Kondo M (1992) A case of optic neuritis associated with anticardiolipin antibodies. Rinsho Shinkeigaku 32:330–332
Marie I, Hervé F, Borg J, Levesque H (2007) Retrobulbar optic neuritis revealing primary anti-phospholipid antibody syndrome. Scand J Rheumatol 36:156–157. https://doi.org/10.1080/03009740701218832
Rajasekaran D, Jayapandian P, Subbaraghavalu G (2009) Primary antiphospholipid antibody syndrome with optic neuritis. J Assoc Physicians India 57:665
Sciascia S, Amigo MC, Roccatello D, Khamashta M (2017) Diagnosing antiphospholipid syndrome: “extra-criteria” manifestations and technical advances. Nat Rev Rheumatol 13:548–560. https://doi.org/10.1038/nrrheum.2017.124
Islam MA, Alam F, Kamal MA, Wong K, Sasongko T, Gan S (2016) “Non-criteria” neurologic manifestations of antiphospholipid syndrome: a hidden kingdom to be discovered. CNS Neurol Disord Drug Targets 15:1253–1265. https://doi.org/10.2174/1871527315666160920122750
Xourgia E, Tektonidou MG (2020) Management of non-criteria manifestations in antiphospholipid syndrome. Curr Rheumatol Rep 22:51. https://doi.org/10.1007/s11926-020-00935-2
Espinosa G, Cervera R (2015) Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 11:586–596. https://doi.org/10.1038/nrrheum.2015.88
Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261:17–26. https://doi.org/10.1007/s00415-013-6957-4
Jang Y, Kim S-M, Yun YI, Lee HJ, Kim SJ, Jung JH, Shin JH (2020) Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci 41:2755–2760. https://doi.org/10.1007/s10072-020-04371-z
Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284. https://doi.org/10.1093/brain/awg045
Lee HJ, Kim B, Waters P, Woodhall M, Irani S, Ahn S, Kim SJ, Kim SM (2018) Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation 15:1–9. https://doi.org/10.1186/s12974-018-1335-x
Liu H, Zhou H, Wang J, Xu Q, Wei S (2019) Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol 103:1423–1428. https://doi.org/10.1136/bjophthalmol-2018-313142
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78:1296–1304. https://doi.org/10.1136/annrheumdis-2019-215213
Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D (2018) Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheum 48:117–120. https://doi.org/10.1016/j.semarthrit.2017.12.006
Acknowledgements
To the patient for allowing us to publish his case and create knowledge.
Author information
Authors and Affiliations
Contributions
Cristian Eduardo Navarro MD MSc: conceptualization, methodology, formal analysis, investigation, writing (original draft), writing (review and editing), and visualization. Gabriel José Arango MD: formal analysis, resources, writing (review and editing), and visualization. María F Cubides MD: formal analysis, resources, writing (review and editing), and visualization.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Ethics approval is not required for case reports at our institution. The patient gave his informed consent to participate in this study.
Consent for publication
The patient gave his informed consent to publish the case and the attached images.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Navarro, C.E., Arango, G.J. & Cubides, M.F. Chronic relapsing inflammatory optic neuropathy in a patient with triple antiphospholipid antibody positivity. Neurol Sci 42, 3439–3443 (2021). https://doi.org/10.1007/s10072-021-05263-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-021-05263-6